Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib neoadjuvant study in EGFR-positive stage IIB-IIIA NSCLC
ChiCTR2100042856Phase 4Recruiting
- Sponsor
- Huadong Hospital, Fudan University
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Huadong Hospital, Fudan University. Primary endpoint: Radical resection rate. Started Feb 2021; status: recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100042856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042856.